Combining knowledge of the business with a clear connection to the science involved, Denner has created the template for the modern-day biotech turnaround story.
"Alex actually understands the science--and how to build that into a business," ex-con and ImClone founder Sam Waksal told Bloomberg. "When a company is broken, he knows what should be done to fix it."
As an inside player, few can compare to Denner. The big question now is where he plans to play next. And who will follow his game book on their own deals?
POZN to be acquired by Reckitt Norwich, England, by the name of J&J Colman. Aspirin market is growing rapidly and POZN likely to get FDA approval in April 2014.
Alex Denner expected to be on Ariad Board by tomorrow - 20th Feb 2014.
Be ready Proxy voting is done and 19th is cut off date.
M&A activities starts with Alex on the Ariad Board and the passage for EliLilly as the history suggest that Eli has secured deals through Alex on board.
POZEN Announces New PA8140/PA32540 PDUFA Date of April 25, 2014
Sarissa Capital disclosed it's meetings of the board of directors of Ariad Pharmaceuticals Inc.
Even with another big acquisition making headlines in the space, it takes a certain degree of faith to invest in drug companies or just about anything in the biotech or pharma space. The Byzantine approval process for new medications, not to mention the seemingly endless unintended consequences related to Obamacare have made it easy to avoid the sector entirely in favor of index funds, ETFs or almost any other asset class.
Where others see nothing but murk, Divine Capital founder Danielle Hughes sees opportunity. In the attached video she explains that the first step in the research process is understanding the growing disconnect between the road to drug approval and modern medicine.
Alex Denner did that same way as things are going for Ariad.
- Genzyme Corp. before its $20.1 billion sale to Paris-based Sanofi
- MedImmune LLC prior to its $15.2 billion acquisition by AstraZeneca Plc (AZN), based in London.